Effects of three acepromazine doses on the incidence of morphine-induced vomiting, sedation and some physiological variables in dogs

Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydromorphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on physiological variables following administration of the combinations tested.Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a randomized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures (SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment and only the incidence of vomiting was assessed. There was no significant difference between groups on the incidence of vomiting recorded in Phase 1, Phase 2 and the average of Phases 1 and 2. A significant decrease in PR was observed in most groups but no significant difference was detected between groups. Blood pressure decreased in all groups; during most of the evaluation period, SAP, MAP and DAP were significantly higher in the Control than in other treatments. Dogs in this study presented mild to intense sedation.[...]

Effects of three acepromazine doses on the incidence of morphine-induced vomiting, sedation and some physiological variables in dogs

Background: Acepromazine was found to reduce the incidence of vomiting induced by opioids such as morphine, hydromorphone and oxymorphone in dogs. Despite the effectiveness of the phenothiazine in preventing opioid-induced vomiting in this species, a single dose of acepromazine (0.05 mg/kg) was tested and the influence of dose on the antiemetic effect of the drug is unknown. The primary objective of this study was to evaluate the effect of three acepromazine doses on the incidence of vomiting induced by morphine in dogs. A secondary aim was to assess the degree of sedation and effects on physiological variables following administration of the combinations tested.Materials, Methods & Results: All dogs received 0.5 mg/kg morphine (IM). Fifteen min before morphine, dogs in the Control, ACPLD, ACPMD and ACPHD groups were administered (IM) physiological saline or acepromazine at doses of 0.025, 0.05 and 0.1 mg/kg, respectively. In Phase 1, purpose-bred dogs (n = 8) underwent each of the four treatments in a randomized, crossover design; the incidence of vomiting, sedation, pulse rate (PR), systolic, mean and diastolic blood pressures (SAP, MAP and DAP) were investigated for 60 min. Sedation was assessed by a numeric descriptive scale (NDS, range 0-3) and a simple numerical scale (SNS, range 1-10). In Phase 2, client-owned dogs (n = 50) received a single treatment and only the incidence of vomiting was assessed. There was no significant difference between groups on the incidence of vomiting recorded in Phase 1, Phase 2 and the average of Phases 1 and 2. A significant decrease in PR was observed in most groups but no significant difference was detected between groups. Blood pressure decreased in all groups; during most of the evaluation period, SAP, MAP and DAP were significantly higher in the Control than in other treatments. Dogs in this study presented mild to intense sedation.[...](AU)

Parâmetros ecocardiográficos em cães saudáveis tratados com acepromazina, meperidina e sua associação / Echocardiographic parameters in healthy dogs treated with acepromazine, meperidine and their association

Objetivou-se avaliar os efeitos da tranquilização com meperidina, acepromazina e de sua associação sobre os parâmetros ecocardiográficos em cães. Foram utilizados 12 cães adultos, da raça Rottweiler, submetidos ao exame ecocardiográfico sem utilização de sedação (controle - TC) e a três protocolos de tratamento, utilizando-se meperidina (TM), acepromazina (TA) e a associação dos medicamentos (TMA). As variáveis foram analisadas pelo teste de Tukey (P<0,05). Observou-se que as médias obtidas na onda A do fluxo mitral em TA e TMA diminuíram significativamente com relação ao TM, que não diferiu do TC. Houve uma diminuição significativa no valor de movimento anular mitral (MAM) e excursão sistólica do plano anular tricúspide (ESPAT) no TA. Não houve diferença significativa para os valores de fração de encurtamento (FE) entre TA e os demais tratamentos. Entretanto, observou-se que 57,3% dos cães apresentaram valores de FE abaixo da normalidade. As alterações encontradas podem ser decorrentes dos efeitos hipotensores da acepromazina utilizada de forma isolada. Conclui-se que a meperidina ou sua associação com acepromazina não alteram os parâmetros ecocardiográficos em cães saudáveis e que a acepromazina, utilizada isoladamente, causa alteração nos parâmetros de função sistólica dos cães, não sendo recomendada para a contenção química dos cães submetidos ao ecocardiograma, o que poderia levar à má interpretação do exame.(AU)

The aim of this study was to evaluate the effects of sedation with meperidine, acepromazine and its association on the echocardiographic parameters in dogs. Twelve adult Rottweilers were used and subjected to the echocardiography examination without the use of sedation (control - CT) and subjected to three treatment protocols using meperidine (MT), acepromazine (AT), and the combination of drugs (MAT). Variables were analyzed by Tukey test (p<0,05). The averages obtained in A-wave of mitral inflow in AT and MAT decreased significantly compared to MT, which did not differ from CT. There was a significant decrease in the measurement of mitral annulus motion (MAM) and tricuspid annular plane systolic excursion (TAPSE) at TA. There was no significant difference in shortening fraction (SF) values between TA and other treatments. However, it was observed that 57.3% of the dogs showed SF values below the normal range for the species. All changes found may be due to the hypotensive effects of acepromazine used in isolation. In conclusion, meperidine or its association with acepromazine does not alter echocardiographic parameters in healthy dogs and acepromazine, used alone, causes changes in the parameters of systolic function and is not recommended for sedation of dogs submitted to echocardiogram, since it could cause a misinterpretation of the exam.(AU)

Parâmetros ecocardiográficos em cães saudáveis tratados com acepromazina, meperidina e sua associação / Echocardiographic parameters in healthy dogs treated with acepromazine, meperidine and their association

Objetivou-se avaliar os efeitos da tranquilização com meperidina, acepromazina e de sua associação sobre os parâmetros ecocardiográficos em cães. Foram utilizados 12 cães adultos, da raça Rottweiler, submetidos ao exame ecocardiográfico sem utilização de sedação (controle - TC) e a três protocolos de tratamento, utilizando-se meperidina (TM), acepromazina (TA) e a associação dos medicamentos (TMA). As variáveis foram analisadas pelo teste de Tukey (P<0,05). Observou-se que as médias obtidas na onda A do fluxo mitral em TA e TMA diminuíram significativamente com relação ao TM, que não diferiu do TC. Houve uma diminuição significativa no valor de movimento anular mitral (MAM) e excursão sistólica do plano anular tricúspide (ESPAT) no TA. Não houve diferença significativa para os valores de fração de encurtamento (FE) entre TA e os demais tratamentos. Entretanto, observou-se que 57,3% dos cães apresentaram valores de FE abaixo da normalidade. As alterações encontradas podem ser decorrentes dos efeitos hipotensores da acepromazina utilizada de forma isolada. Conclui-se que a meperidina ou sua associação com acepromazina não alteram os parâmetros ecocardiográficos em cães saudáveis e que a acepromazina, utilizada isoladamente, causa alteração nos parâmetros de função sistólica dos cães, não sendo recomendada para a contenção química dos cães submetidos ao ecocardiograma, o que poderia levar à má interpretação do exame.(AU)

The aim of this study was to evaluate the effects of sedation with meperidine, acepromazine and its association on the echocardiographic parameters in dogs. Twelve adult Rottweilers were used and subjected to the echocardiography examination without the use of sedation (control - CT) and subjected to three treatment protocols using meperidine (MT), acepromazine (AT), and the combination of drugs (MAT). Variables were analyzed by Tukey test (p<0,05). The averages obtained in A-wave of mitral inflow in AT and MAT decreased significantly compared to MT, which did not differ from CT. There was a significant decrease in the measurement of mitral annulus motion (MAM) and tricuspid annular plane systolic excursion (TAPSE) at TA. There was no significant difference in shortening fraction (SF) values between TA and other treatments. However, it was observed that 57.3% of the dogs showed SF values below the normal range for the species. All changes found may be due to the hypotensive effects of acepromazine used in isolation. In conclusion, meperidine or its association with acepromazine does not alter echocardiographic parameters in healthy dogs and acepromazine, used alone, causes changes in the parameters of systolic function and is not recommended for sedation of dogs submitted to echocardiogram, since it could cause a misinterpretation of the exam.(AU)

Avaliação eletrocardiográfica e da pressão arterial de gatos-do-mato pequenos submetidos à neurolepanalgesia com a associação dexmedetomidina, midazolan e petidina / Electrocardiographic evaluation and blood pressure of smalls oncilla undergoing neurolepanalgesia association with dexmedetomidine, midazolam and pethidine

Desta forma, objetivou-se com este trabalho avaliar a associação de dexmedetomidina, midazolan e petidina sobre os parâmetros eletrocardiográficos e da pressão arterial de gatos-do-mato pequenos. Foram utilizados seis gatos-do-mato pequenos, três machos e três fêmeas, provenientes do CETAS/ IBAMA de JP/ PB. Estatisticamente, observou-se variação no intervalo QT e na PAS. Variações além dos limites referenciais foram observados na FC, Pms, segmento ST e PAS. A associação dexmedetomidina-midazolan-petidina, nas doses empregadas neste experimento, não conduziu alterações de ordem eletrocardiográficas e de PA que elevem o protocolo a contra-indicação em gatos-do-mato pequenos, sendo uma alternativa segura para contenção farmacológica nesta espécie por um período não superior a 40 minutos.

The objective of this study was to evaluate the association of dexmedetomidine, midazolam and pethidine on electrocardiographic parameters and blood pressure in cats of the woods small. We used six cats of the woods small, three males and three females, from the CETAS/ IBAMA JP/ PB. Statistically, there was variation in the QT interval and PAS. Variations beyond the limits benchmarks were observed in FC, Pms, ST and PAS. The association dexmedetomidine-midazolam-pethidine in doses used in this experiment did not lead electrocardiographic changes in order to elevate PA and the protocol contraindicated in smalls Oncilla, with a safe alternative to chemical restraint in this species by a period not exceeding 40 minutes.